A Randomised, Parallel, Single-Dose, Subcutaneous Injection, Phase I Clinical Study Of HLX14 Versus Prolia (Denosumab) In Chinese Healthy Adult Male Subjects For Comparison In Pharmacokinetic Characteristics, Safety, And Immunogenicity
Latest Information Update: 21 Mar 2024
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis; Solid tumours
- Focus Pharmacokinetics
- Sponsors Shanghai Henlius Biotech
- 01 Feb 2024 Status changed to completed.
- 01 Feb 2024 According to a Henlius Biopharmaceuticals media release,Primary endpoint has been met. (AUC0-inf)
- 01 Feb 2024 According to a Henlius Biopharmaceuticals media release, Primary endpoint has been met. (Cmax)